Navigation Links
Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
Date:5/22/2008

SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the FBR Capital Markets Investor Conference in New York on Wednesday, May 28, 2008 at 9:45 a.m. ET / 6:45 a.m. PT. David M. Kendall, M.D., Executive Director, Medical Affairs of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte ...l oral JAK2 inhibitor, SB1518, at The American Soc...ion in New Orleans. ,, Data will be presented o...ation trial of SB1518 detailing its safety, tolera... profile in dose levels ranging from 100 to 600 mg...
(Date:12/2/2009)..., SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The w... are in turmoil and uncertainty is part of many,bu...rma industry has been,relatively immune to the eco...ation. , During the midst of the difficul...n & Johnson inaugurated an R&D center in S...
(Date:12/1/2009)...NCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall...day announced revenue guidance for the fourth quar...illion, as compared with $69 million for the fourt... results was the first of two installment payments...fourth quarter 2008 results was a one-time $1.8 mi...
(Date:12/1/2009)...PLYMOUTH, Mass., Dec. 1 Harvest Te... today results from the company sponsored 60-patie...ical Center in Chennai, India using the company,s ...able Critical Limb Ischemia (CLI). Sri Ramachandra...-associated institution based in Chennai, India an...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...VER, Mass., Oct. 8 Millstone Medical Outsourcing,...cility in Fall River, MA,to accommodate growing bu...w for additional clean room operations. The new fa...,000 square feet of space that allows,increased ca...c cleaning,and sterile and non-sterile packaging. ...
...HMOND, Calif., Oct. 8 Transcept Pharmaceuticals,I...pany, announced today,that Thomas P. Soloway, Seni...cheduled to present at the Natixis Bleichroeder Se...y on Monday, October 13, 2008 at 9:30 AM,Eastern T...e available at, http://www.wsw.com/webcast/nblr2/t...
...e Review With Drs. William F. Fearon, Morton J. Ke...the Highlights, WILMINGTON, Massachusetts, Octobe...optimizing patient outcomes is the topic,of multip...cular,Therapeutics symposium, TCT 2008, which will...Medical Systems, the first company to develop syst...
Other Biology Technology:Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity 2Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2Radi Medical Systems Announces Schedule for TCT 2008 2
(Date:12/3/2009)...eve that staph infections are caused by many bacte...The signaling process is called quorum sensing bec...ocess. , But the Jeff Brinker research group has...ection, when bacteria switch from a harmless to a ...is individual process can be stopped by the applic...
(Date:12/3/2009)...evels for the past three years in the troposphere ... area near Valladolid. The results, which are the ... that the levels rose "significantly" between 2002...eteorologists have been trying to find out about c...lved in the troposphere over various urban and rur...
(Date:12/2/2009)...o men have a more difficult time quitting smoking ...re, but acculturation has no affect on Latinas odd...re published in Cancer Epidemiology, Biomarkers &...n for Cancer Research. The December issue has a sp... smoking cessation differently for Latino men and ...
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3CO2 levels rising in troposphere over rural areas 2Acculturation affects smoking cessation success among Latinos 2Cradle and birthday of dog identified 9751 1Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 1Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 2Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 3Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 1Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 2Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 3Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 4Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 5Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 6Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 7Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 8
...A study financed by the BBVA Foundation and conduc...uria Marb from the Mediterranean Institute for Ad...slands) has allowed the first-time formulation of ...plant communities, showing how plants assure the s...a day or are prolonged over centuries. , The rese...
...A joint Canadian-American research team have, for ...ations in fish respond directly to changes in atmo...ional teams research began in 2001 at the Experime...this weeks Proceedings of the National Academy of ...icult to establish because of all the other factor...
...GREENBELT, Md. -- The NASA-managed Sea-viewing Wid...d into orbit around Earth in 1997 and took its fir...e satellite,s data has proved instrumental in coun...picture of a changing climate. NASA recognized the...s at the Goddard Space Flight Center in Greenbelt,...
Other Biology News:A study proposes a new universal rule to explain the equilibrium of plant populations 2International team shows mercury concentrations in fish respond quickly to increased deposition 2NASA celebrates a decade observing climate impacts on health of world's oceans 2NASA celebrates a decade observing climate impacts on health of world's oceans 3
Random DNA mutagenesis Service from Yorkshire Bioscience Ltd
...ed solution for scheduling, performing and documen...ing for all pipettes and liquid handling devices. ...orts all gravimetric calibration protocols Meets...irements Includes setup information for balances...
...ee plasmid DNA preparations are prepared from cust...1mg to multi-gram scales. Small-scale (1-100mg) a...ons are made according to customer specifications....omer needs, and glycerol stocks are maintained to ...
...ones which belong to the transforming growth facto...arge group of extra-cellular growth factors which ...function and tumor formation (1). Other members in...fferentiation factors, AMH/MIS (Anti-Mullerian Hor...
Biology Products: